The recent discovery of the SWI/SNF complex as an essential player in determining the therapeutic efficacy of cancer immunotherapy further highlights great promise for harnessing the cancer-specific vulnerability elicited by ARID1A deficiency to potentiate immunotherapy. Here, ARID1A is linked to cancer.